Cancer Genetic Testing (CGx) DNA cancer testing

Hereditary or Predispostion Cancer Genomics

Molecular testing looks for specific inherited changes (mutations) in a person's genetic make-up.  Genetic mutations may have multiple different effects on a person's health.  Mutations that are harmful may increase a person's chance or risk of developing a disease such as cancer.  Inherited mutations are thought to play a role in 10% of all cancers.  These particular conditions are considered hereditary and appropriate genetic testing may be used to determine an individuals's risk.  

Some people inherit mutations in the germ line allowing for the mutations to be passed on from their parents and to their children.  There are two classes of cellular genes:  oncogenes and tumor suppressor genes.  Often multiple genetic mutations in a single individual are responsible for the development of hereditary cancers.  

Genetic counseling and testing may be recommended for people who have had certain cancers or certain patterns of cancer in their family.

If you have any of the following you might consider CGX testing:

  • Several first-degree relatives (mother, father, sisters, brothers, children) with cancer.
  • Many relatives on one side of the family who have had the same type of cancer.
  • A cluster of cancers in your family that are known to be linked to a single gene mutation (such as breast, ovarian and pancreatic cancers in your family).
  • A family member with more than 1 type of cancer.
  • Close relatives with cancers that are linked to rare hereditary cancer syndromes. 
  • A family member with a rare cancer such as breast cancer in a male or retinoblastoma.
  • Ethnicity (for example Jewish ancestry is linked to ovarian and breast cancers).
  • A physical finding that's linked to an inherited cancer (such as having many colon polyps).
  • A known genetic mutation in one or more family members who have already had genetic testing.

KNOWLEDGE Is Power.  Learn about YOUR  Risk of Developing Cancer.


Pharmacogenomics Testing (PGX)

The next generation of regenerative medicine

95% of people have at least 1 gene variation that will affect how well drugs will work with their body.

Patients have differences in DNA that impact drug metabolism which may increase their likelihood of an adverse drug reaction:

More than 85% of the population have detectable variations in their DNA that increase their risk for adverse drug reactions.  

Adverse drug reactions are the 4th leading cause of death nationwide with more than 8.6 million cases reported annually. The FDA highlights pharmacogenomics data for more than 130 prescription medications indicating their strong support for testing.


Pharmacogenomics is the study of genetic variations that influence an individual's response to drugs.  Each person responds uniquely to treatment so the same approach may not be effective or may cause adverse drug effects in other patients.  The implementation of PGX testing helps physicians make informed treatment decisions.  This will lead to better outcomes by decreasing adverse drug events and by increasing the effectiveness of drugs.  


You are candidate for PGX testing if you meet one or more of the following conditions:

You experience less than optimal results from prescribed medications.

People with a personal or family history of adverse drug reactions in response to certain medications.

People taking multiple prescriptions medications for multiple chronic conditions.  


Finding the medication that works best for you shouldn't be a guessing game.  Asimple cheek swab can reveal which medications may cause side effects or even dangerous adverse reactions the cause of more than 100,000 deaths in the U.S. each year. 


With knowledge of your genetic makeup treatments can be tailored uniquely to you.  

Our PGX testing reports details how your body metabolizes medications and suggests alternative prescriptions when increased sensitivity or reduced response is likely. 


Various Medication Classes can be ineffective for 20-75% of treated patients.
Various Medication Classes can be ineffective for 20-75% of treated patients.